EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immune Dysregulation as a Key Driver of Peripartum Cardiomyopathy – an Exploratory Advanced Imaging and Biomarker Study

Julian Hoevelmann iD, Charle Viljoen iD, Tessa Kotze, Carlos Libhaber, Stephen Jermy, Morné Kahts, Fareda Jakoet-Bassier, Petronella Samuels, Olivia Briton, Lynette Cilliers, Denise Hilfiker-Kleiner, Peter van der Meer und 3 weitere

European Journal of Heart Failure · 2025

DOI: 10.1002/ejhf.3759 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Heart Failure, 2025. Verfasst von Julian Hoevelmann und 14 weiteren Autor:innen. Beteiligte Einrichtung: Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa. Hauptthemen laut MEDLINE: Cardiomyopathies, Pregnancy Complications, Cardiovascular, Puerperal Disorders. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Stiftung fr Herzforschung, Deutsche Stiftung für Herzforschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Peripartum cardiomyopathy (PPCM) is an idiopathic cardiomyopathy occurring in women in the late stages of pregnancy or in the postpartum period and is associated with significant morbidity, mortality, and persistent left ventricular dysfunction. PPCM pathogenesis involves multiple putative mechanisms including inflammation. We aimed to explore the acute inflammatory processes in PPCM using 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18FDG-PET-CT), cardiovascular magnetic resonance (CMR), and inflammasome profiling. Methods and results Women with a new diagnosis of PPCM (n = 10, all within 3 months postpartum), five healthy postpartum controls (HPC), and five healthy non-postpartum controls (HNPC), underwent 18FDG-PET-CT, CMR, and serum inflammatory proteomic profiling. PPCM patients had a median age of 34 years (interquartile range [IQR] 30.3–38.5, similar in control groups), and a median parity of 3 (IQR 1–4). PPCM patients presented with severe, symptomatic heart failure (all New York Heart Association functional class III/IV), reduced median left ventricular ejection fraction of 35.5% (IQR 18.1–37.9). PPCM and HPC groups showed higher myocardial and splenic 18FDG uptake compared to HNPC. On CMR, myocardial interstitial fibrosis (elevated T1 time, extracellular volume, and late gadolinium enhancement mass) was solely present in PPCM. Inflammatory profiling showed pro-inflammatory cytokine dysregulation in PPCM (elevated neutrophil-to-lymphocyte ratio, C-reactive protein, interleukin-6, tumour necrosis factor-α, chemokine (C-C motif) ligand 3, hepatocyte growth factor, chemokine (C-X-C motif) ligand 10 and colony-stimulating factor-1) compared to controls.

Conclusions

Patients with PPCM exhibited a dysregulated immune response, associated with early myocardial interstitial fibrosis and adverse cardiac remodelling. This highlights the importance of rapid initiation of guideline-directed medical therapy especially with drugs documented to have anti-fibrotic effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CardiomyopathiesPregnancy Complications, CardiovascularPuerperal DisordersHumansFemaleAdultPregnancyPeripartum PeriodBiomarkersPositron Emission Tomography Computed TomographyMagnetic Resonance Imaging, CineFluorodeoxyglucose F18Stroke VolumeVentricular Function, LeftPeripartum Cardiomyopathy

Stichwörter der Autor:innen

Cardiovascular magnetic resonanceImmune responsePeripartum cardiomyopathyPositron emission tomography

Substanzen

BiomarkersFluorodeoxyglucose F18

Autor:innen und Institutionen

  • Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
  • Department of Internal Medicine III - Cardiology, Angiology and Intensive Care Medicine, Saarland University Hospital, Saarland University, Homburg, Germany.
  • Division of Cardiology, Groote Schuur Hospital, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
  • Cape Universities Body Imaging Centre, University of Cape Town, Cape Town, South Africa.
  • School of Physiology, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
  • Division of Biomedical Engineering, Department of Human Biology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.

ORCID-Profile: Julian Hoevelmann, Charle Viljoen, Karen Sliwa

Förderung

  • Deutsche Stiftung fr Herzforschung
  • Deutsche Stiftung für Herzforschung

Zitieren

APA

Hoevelmann, J., Viljoen, C., Kotze, T., Libhaber, C., Jermy, S., Kahts, M., Jakoet-Bassier, F., Samuels, P., Briton, O., Cilliers, L., Hilfiker-Kleiner, D., van der Meer, P., Böhm, M., Ntusi, N. A. B., & Sliwa, K. (2025). Immune Dysregulation as a Key Driver of Peripartum Cardiomyopathy – an Exploratory Advanced Imaging and Biomarker Study. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3759

Vancouver

Hoevelmann J, Viljoen C, Kotze T, Libhaber C, Jermy S, Kahts M, et al. Immune Dysregulation as a Key Driver of Peripartum Cardiomyopathy – an Exploratory Advanced Imaging and Biomarker Study. European Journal of Heart Failure. 2025. doi:10.1002/ejhf.3759

BibTeX
@article{Hoevelmann2025,
  author = {Hoevelmann, Julian and Viljoen, Charle and Kotze, Tessa and Libhaber, Carlos and Jermy, Stephen and Kahts, Morné and Jakoet-Bassier, Fareda and Samuels, Petronella and Briton, Olivia and Cilliers, Lynette and Hilfiker-Kleiner, Denise and van der Meer, Peter and Böhm, Michael and Ntusi, Ntobeko A B and Sliwa, Karen},
  title = {Immune Dysregulation as a Key Driver of Peripartum Cardiomyopathy – an Exploratory Advanced Imaging and Biomarker Study},
  journal = {European Journal of Heart Failure},
  year = {2025},
  doi = {10.1002/ejhf.3759}
}
Kostenlos starten →